nuvaxovid - Search News

Order byBest matchMost fresh

Nuvaxovid FDA Approval Unlocks Several Bullish Stimuli

Novavax: Nuvaxovid FDA Approval Unlocks Several Bullish Stimuli

The approval positions Novavax as the only non-mRNA COVID-19 vaccine with full FDA approval, offering a differentiated alternative amid growing mRNA fatigue.

· 1d

Infectious Disease Advisor · 1d

FDA Approves Novavax’s COVID-19 Vaccine Nuvaxovid

PharmExec · 2d

FDA Grants Full Approval to Novavax’s Nuvaxovid COVID-19 Vaccine

F.D.A. Poised to Restrict Access to Covid Vaccines

Citing low uptake of recent Covid shots, “the American people, along with many health care providers, remain unconvinced” that the shots are needed, the officials said.

· 1d

· 5h

US FDA Advisers to Weigh Composition of COVID Vaccines for 2025-2026

· 1d

FDA plans to limit COVID vaccine to only high-risk people. Who would still be eligible?

Zacks Investment Research on MSN3h

Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More

Mergers and acquisitions grabbed the spotlight in the biotech sector once again this week after BioMarin BMRN agreed to acquire Inozyme Pharma INZY. Meanwhile, other pipeline and regulatory updates were in focus.

BMRN to Acquire Inozyme Pharma

Mergers and acquisitions grabbed the spotlight in the biotech sector once again this week after BioMarin BMRN agreed to acquire Inozyme Pharma INZY. Meanwhile, other pipeline and

1don MSN

BofA Reiterates Hold Rating on Novavax (NVAX) Stock

BofA analyst Alec Stranahan reiterated a Hold rating on Novavax, Inc. (NASDAQ:NVAX) stock, setting a price target of $10. The approval of Nuvaxovid for use in older and high-risk adults will generate around $175 million in milestone payments from Sanofi during Q3 and an additional $50 million in the second half of

Explore more

Novavax

COVID-19

Food and Drug Administration